The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
Phase 2
Completed
- Conditions
- Heart Failure, CongestiveDyspneaPulmonary Edema
- Registration Number
- NCT00043836
- Lead Sponsor
- Synvista Therapeutics, Inc
- Brief Summary
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic heart failure (DHF), and that the improvements in exercise tolerance will correlate with the improvements in aortic distensibility.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Wake Forest University Baptist Medical Center, Department of Cardiology
🇺🇸Winston-Salem, North Carolina, United States
Medical University of South Carolina and Ralph H. Johnson VA Medical Center
🇺🇸Charleston, South Carolina, United States